Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 1/20 | 0.51 |
| ▸ | MKNK1 | Q9BUB5 | 11/20 | 0.51 |
| ▸ | MKNK2 | Q9HBH9 | 11/20 | 0.51 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.51 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
| ▸ | PIM1 | P11309 | 2/20 | 0.46 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.45 |
| ▸ | AXL | P30530 | 1/20 | 0.45 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.44 |
| ▸ | BRAF | P15056 | 1/20 | 0.43 |
| ▸ | RET | P07949 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30516607 | 0.93 | CYP2E1 (0.57) | MKNK1MKNK2CYP2E1CYP2A6CYP2C9 | |
| SCHEMBL6872027 | 0.93 | CYP2E1 (0.57) | MKNK1MKNK2CYP2E1CYP2A6CYP2C9 | |
| SCHEMBL3986274 | 0.90 | MKNK1 (0.57) | MKNK1MKNK2CYP2E1CYP2A6CYP2C9 | |
| SCHEMBL3988485 | 0.86 | RAB9A (0.43) | MKNK2PIM1MEN1USP30KMT2A | |
| SCHEMBL370074 | 0.80 | CYP2E1 (0.55) | KMOMKNK1MKNK2CYP2E1CYP2A6 | |
| SCHEMBL30516614 | 0.80 | CYP2E1 (0.55) | KMOMKNK1MKNK2CYP2E1CYP2A6 | |
| SCHEMBL23930645 | 0.79 | CYP2A6 (0.54) | KMOCYP2E1CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL3989808 | 0.79 | RAB9A (0.47) | MEN1KMT2ARXFP1 | |
| SCHEMBL368446 | 0.79 | CYP2C9 (0.54) | KMOMKNK1MKNK2CYP2E1CYP2A6 | |
| SCHEMBL3985673 | 0.78 | RAB9A (0.64) | CYP2C9CYP2C19MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1893572-B1 | FACTOR XA INHIBITORS | MILLENNIUM PHARM INC (US) | 2016-12-14 | — | — | EP | claimed |
| US-20090298806-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2009-12-03 | — | — | US | claimed |
| US-20060100193-A1 | 5-Chloro-N-((1-(4-(2-oxopyridin-1(2H)-yl)phenyl)-1H-1,2,3-triazol-4-yl)methyl)thiophene-2-carboxamide; 5-Chloro-thiophene-2-carboxylic acid (3-p-tolyl-4,5-dihydro-isoxazol-5-ylmethyl)-amide; undesirable thrombosis inhibitor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-05-11 | — | — | US | claimed |
| EP-1893572-B1 | FACTOR XA INHIBITORS | MILLENNIUM PHARM INC (US) | 2016-12-14 | — | — | EP | disclosed |
| US-8377974-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-20120178733-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2012-07-12 | — | — | US | disclosed |
| US-20090298806-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2009-12-03 | — | — | US | disclosed |
| US-7521470-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-04-21 | — | — | US | disclosed |
| EP-1893572-A2 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-03-05 | — | — | EP | disclosed |
| US-20060100193-A1 | 5-Chloro-N-((1-(4-(2-oxopyridin-1(2H)-yl)phenyl)-1H-1,2,3-triazol-4-yl)methyl)thiophene-2-carboxamide; 5-Chloro-thiophene-2-carboxylic acid (3-p-tolyl-4,5-dihydro-isoxazol-5-ylmethyl)-amide; undesirable thrombosis inhibitor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-05-11 | — | — | US | disclosed |
| WO-2006002099-A2 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100193-A1 | 5-Chloro-N-((1-(4-(2-oxopyridin-1(2H)-yl)phenyl)-1H-1,2,3-triazol-4-yl)methyl)thiophene-2-carboxamide; 5-Chloro-thiophene-2-carboxylic acid (3-p-tolyl-4,5-dihydro-isoxazol-5-ylmethyl)-amide; undesirable thrombosis inhibitor | TFPI, TFPI2, F12 | KMO 778/4885MKNK1 3512/4885MKNK2 3410/4885 |
| US-20090298806-A1 | FACTOR XA INHIBITORS | TFPI, F12, F11 | KMO 748/4885MKNK1 4374/4885MKNK2 4325/4885 |
| US-20120178733-A1 | FACTOR XA INHIBITORS | TFPI, F12, F11 | KMO 748/4885MKNK1 4374/4885MKNK2 4325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.